# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2017 Vol. 45, No. 10

## CONTENTS

### ANNOUNCEMENT

Announcement. Mary Vore .......................... 1101

### PERSPECTIVE

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control. 
Niresh Hariparsad, Diane Ramsden, Jairam Palamanda, Joshua G. Dekeyser, Odette A. Fahmi, Jane R. Kenny, Heidi Einolf, Michael Mohutsky, Magalie Pardon, Y. Amy Siu, Liangfu Chen, Michael Sing, Barry Jones, Robert Walsky, Shannon Dallas, Suresh K. Balani, George Zhang, David Buckley, and Donald Tweedie ............................ 1049

### ARTICLES


Involvement of Nuclear Factor κB, not Pregnane X Receptor, in Inflammation-Mediated Regulation of Hepatic Transporters. Walaa A. Abualsunun and Micheline Piquette-Miller .......................... 1077


Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by \([^{11}C]\)erlotinib and Positron Emission Tomography. Alexander Traxl, Karin Komposch, Elisabeth Glitzer, Thomas Wanek, Severin Mauringer, Oliver Langer, and Maria Sibilia .......................... 1093


### ERRATUM

Correction to “Identification of genetic polymorphisms of CYP2W1 in the three main Chinese ethnicities: Han, Tibetan, and Uighur”. .......................... 1113

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Representative co-registered coronal whole-body \([^{11}C]\)erlotinib PET summation (0–90 minutes) and MR (T1-weighted gradient echo sequence) images of an EGFR\(^{+/+}\) (left) and an EGFR\(^{\Delta \text{hep}}\) mouse. See the article by Langer et al., (dx.doi.org/10.1124/dmd.117.077081).